Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Imugene Sets Azer-Cel Milestones, Reports 77% Phase 1b Response Rate

Imugene Limited (IMU) · Health care

IMU: $0.034 -5.56% · MC: $20M

At its AGM, Imugene said azer-cel had a 77% response rate across Phase 1b patients, with early BTK-inhibitor combination data showing an 86% response rate; the company cautioned that the combination results are early. It expects to complete Phase 1b enrolment in the second quarter of 2027, plans an FDA meeting in mid-2027 to discuss the registration pathway, and is targeting a registrational study in the second half of 2027 or 2028, while out-licensing discussions are underway. The AGM also approved all resolutions, and non-executive director Lesley Russell resigned, prompting committee changes.

Source announcements: 2026-11-11 08:50 to 2026-11-11 14:02 Sydney time
Story updated 2026-11-11 14:04 Sydney time
SourcesAGM PresentationResults of 2026 Annual General MeetingDirector Resignation and Committee Changes
Comments